Literature DB >> 8977284

Homeostatic regulation of CD8+ T cells after antigen challenge in the absence of Fas (CD95).

C Zimmermann1, M Rawiel, C Blaser, M Kaufmann, H Pircher.   

Abstract

The role of Fas in the homeostatic regulation of CD8+ T cells after antigen challenge was analyzed in the murine model of lymphocytic choriomeningitis virus (LCMV) infection. Mice homozygous for the lpr mutation and carrying T cell receptor (TCR) alphabeta transgenes specific for the LCMV glycoprotein peptide aa 33-41 in the context of H-2Db were used. Five main results emerged: first, development of lymphadenopathy and of CD4- CD8- double-negative B220+ T cells in lpr mice was not inhibited by the alphabeta TCR transgenes; second, tolerance induction and peripheral deletion of CD8+ T cells induced by LCMV glycoprotein peptide injection was independent of Fas expression; third, clonal down-regulation of Fas-deficient TCR-transgenic CD8+ T cells after acute LCM virus infection was identical to the decline of transgenic T cells expressing Fas; fourth, in vivo activated CD8+ effector T cells from TCR transgenic and TCR-lpr/lpr mice were equally susceptible to activation-induced cell death in vitro; and fifth, transgenic effector T cells from lpr/lpr mice were cleared in the declining phase of the immune response in vivo without giving rise to CD4- CD8- double-negative T cells. Taken together, these data suggest that the homeostatic regulation of CD8+ T cells after antigen challenge in vivo is regulated by mechanisms that do not require Fas.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8977284     DOI: 10.1002/eji.1830261215

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  16 in total

Review 1.  Differences in the regulation of CD4 and CD8 T-cell clones during immune responses.

Authors:  P C Beverley; M K Maini
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-03-29       Impact factor: 6.237

2.  CD8(+) T-cell selection, function, and death in the primary immune response in vivo.

Authors:  M F Callan; C Fazou; H Yang; T Rostron; K Poon; C Hatton; A J McMichael
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

Review 3.  Mechanisms of self-nonself discrimination and possible clinical relevance.

Authors:  Carolin Daniel; Jens Nolting; Harald von Boehmer
Journal:  Immunotherapy       Date:  2009-07       Impact factor: 4.196

4.  The Bcl-2 family pro-apoptotic molecule, BNIP3 regulates activation-induced cell death of effector cytotoxic T lymphocytes.

Authors:  J Wan; D Martinvalet; X Ji; C Lois; S M Kaech; U H Von Andrian; J Lieberman; R Ahmed; N Manjunath
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

Review 5.  CD95, BIM and T cell homeostasis.

Authors:  Philippe Bouillet; Lorraine A O'Reilly
Journal:  Nat Rev Immunol       Date:  2009-07       Impact factor: 53.106

6.  Role of tumor necrosis factor receptors in regulating CD8 T-cell responses during acute lymphocytic choriomeningitis virus infection.

Authors:  M Suresh; Anju Singh; Christopher Fischer
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

7.  Concerted action of the FasL/Fas and perforin/granzyme A and B pathways is mandatory for the development of early viral hepatitis but not for recovery from viral infection.

Authors:  S Balkow; A Kersten; T T Tran; T Stehle; P Grosse; C Museteanu; O Utermöhlen; H Pircher; F von Weizsäcker; R Wallich; A Müllbacher; M M Simon
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

Review 8.  Intertwined pathways of programmed cell death in immunity.

Authors:  Stephen M Hedrick; Irene L Ch'en; Bryce N Alves
Journal:  Immunol Rev       Date:  2010-07       Impact factor: 12.988

9.  Mutation in the Fas pathway impairs CD8+ T cell memory.

Authors:  Renu Dudani; Marsha Russell; Henk van Faassen; Lakshmi Krishnan; Subash Sad
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

10.  Apoptosis mediated by Fas but not tumor necrosis factor receptor 1 prevents chronic disease in mice infected with murine cytomegalovirus.

Authors:  M Fleck; E R Kern; T Zhou; J Podlech; W Wintersberger; C K Edwards; J D Mountz
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.